REPL:NASDAQReplimune Group, Inc. Analysis

Replimune (REPL) is trading at $4.70, well above the analyst mean target of $3.50 and the median target of $2.00, indicating potential overvaluation. The stock sits below its 20‑day SMA (3.50) and 50‑day SMA (5.00) while the 200‑day SMA sits near $6.79, confirming a bearish longer‑term trend. Technical momentum is mixed: RSI is modest at 55, MACD shows a bullish histogram (+0.35) with the signal line turning bullish, yet price remains constrained between a support of $1.88 and resistance near $5.54. Fundamentally, the company reports zero revenue, negative EBITDA of $‑319 M, and a trailing EPS of $‑3.44, with a forward PE of –2.26 and a max drawdown of –86.5%. Volatility is extreme at 371% over the past 30 days, though beta is modest at 0.70, suggesting market‑wide swings dominate price moves. The balance sheet shows $269 M cash offset by $76 M debt, giving a debt‑to‑equity of 36%, but operating cash flow remains deeply negative.
Recent material news has added pressure: the FDA rejected a key product candidate, prompting public defense by FDA Commissioner Marty Makary and sparking investor concern, while a Pomerantz Law Firm investigation into potential investor claims further heightens regulatory and legal risk. Conversely, a brief rally followed Health Secretary Robert F. Kennedy Jr.’s comments distancing himself from the FDA decision, and some analysts have issued a “Buy” rating based on the pipeline’s upside. Nevertheless, the combination of high volatility, negative earnings, and ongoing regulatory uncertainty underscores a high‑risk profile that outweighs short‑term upside potential.